Adtraza subcutaneous injection 150 mg syringe

Adtraza subcutaneous injection 150 mg syringe, manufactured by Leo Pharma, contains tralokinumab (genetical recombination). This human monoclonal antibody is used to treat moderate to severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older when topical treatments are insufficient. It is supplied as 150mg 1mL 1 tube with YJ code 4490409G1022.